Quantcast

Latest Immunosuppressive drug Stories

2010-05-25 08:58:19

Researchers have identified a distinct pattern of gene expression in the largest reported group of kidney transplant recipients who have not rejected the transplant kidneys even though they stopped taking anti-rejection drugs. This finding may help identify other transplant recipients who could safely reduce or end use of immunosuppressive therapy. In 2008, more than 80,000 people in the United States were living with a kidney transplant. The findings come from the Immune Tolerance Network...

2010-05-25 08:06:13

Three new reports describe biomarkers that identify either kidney transplant recipients likely to maintain excellent and stable allograft function in the absence of immunosuppressive drugs or those at risk of losing their transplants. Peter Heeger and Bernd Schröppel, at Mount Sinai School of Medicine, New York, describe in an accompanying commentary, the importance of these studies and how they might impact the management of patients in the clinic to provide a more personalized...

2010-05-12 06:00:00

PRINCETON, N.J., May 12 /PRNewswire-FirstCall/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today that patient enrollment has been completed in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of orBec® for the prevention of acute Graft-versus-Host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) with myeloablative conditioning regimens. The study...

2010-05-10 06:00:00

PRINCETON, N.J., May 10 /PRNewswire-FirstCall/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biotechnology company, announced today that the European Patent Office granted patent EP 1392321 "Method of Treating Inflammatory Disorders of the Gastrointestinal Tract using Topically Active Corticosteroids." The new patent's main claims cover the use of topically active corticosteroids in orally administered dosage forms that act concurrently in the upper...

2010-05-03 10:42:27

Two-year results from phase III clinical trials show the experimental immunosuppressive drug belatacept can better preserve kidney function in kidney transplant recipients while preventing graft rejection when compared with the standard immunosuppressive drug cyclosporine. The two-year results from the three-year BENEFIT (Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial) and BENEFIT-EXT ("extended criteria") studies were presented Sunday at the...

2010-04-30 11:50:32

Kidney transplant recipients are known to have a higher risk of cancer, compared to the general population, due to the need to take immunosuppressive drugs to prevent organ rejection. Results published today from a significant, long-term study suggest that no single medication appears to increase this cancer risk. Evaluating data from 1983 in a randomized trial, researchers were able review trends among 481 patients over 20 years - providing the strongest evidence to date on the issue. A...

2010-04-30 09:06:33

Drugs taken by kidney transplant recipients to prevent organ rejection carry similar risks of cancer, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results suggest that no single medication is to blame for the higher incidence of cancer seen among patients who have undergone transplantation. Individuals who receive a kidney transplant have an increased risk of developing cancer compared with the general population....

2010-04-21 10:30:00

ADDISON, Texas, April 21 /PRNewswire/ -- The International Society for Heart and Lung Transplantation (ISHLT) today announces new guidelines to standardize care for heart transplant patients worldwide. The guidelines demonstrate a united effort to decrease complications, improve outcomes and increase patient survival rates among heart transplant recipients. The guidelines will be presented during today's symposium The ISHLT Guidelines for Heart Transplant Recipients: Towards an...

2010-03-25 13:23:39

Sirolimus-based immunosuppression and radiofrequency ablation are promising treatments for HCC A recent study found that sirolimus-based immunosuppression following liver transplantation in patients with non-resectable hepatocellular carcinoma (liver cancer) significantly increases survival rates for this patient population. Results of this study appear in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver...

2010-03-04 08:04:01

The experimental drug belatacept can prevent graft rejection in kidney transplant recipients while better preserving kidney function when compared with standard immunosuppressive drugs, data from two international phase III clinical trials show. The results are published in the March issue of the American Journal of Transplantation. The senior author of the paper describing BENEFIT (Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial) is Christian P....


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related